Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The user experienced significant hair regrowth and improved hair quality after six months of using oral minoxidil, finasteride, and micro-needling. They reported increased libido initially but no other side effects, and they plan to continue the treatment.

A 52-year-old with Norwood 6 hair loss shows progress after 5 months using topical dutasteride, LLLT, copper peptides, Ulo serum, Minoxidil, cetirizine, and microneedling. Native hair is regrowing from vellus to terminal, with increased density in previously bald areas.

The user is undergoing Mesotherapy and Low-Level Laser Therapy for hair loss, with plans for multiple sessions. They are also using oral finasteride, topical minoxidil, dutasteride, and hair fibers.

A user shared their 7-month progress using oral minoxidil (2.5mg) and recently started finasteride (1mg) daily, reporting significant hair improvement without side effects. They noticed thicker beard growth and some hair thickening at the crown, with no shedding phase yet.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

The user has been using a regimen of 0.1% topical finasteride and 5% minoxidil for two years to manage hair loss, with micro-needling twice a month. They report maintaining hair density despite cycles of shedding, emphasizing the importance of consistency in treatment.

A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.

User shared 9 months of progress using 1 mg finasteride and topical minoxidil, showing photos from different stages. Encouragement was given to continue the treatment.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

A user is concerned about a change in the formula of Sons topical treatment, which now requires fewer sprays but contains less minoxidil. They question if the change is for convenience or if it's a way to charge the same for less product.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

The user showed 2-3 years of hair regrowth progress using oral finasteride, topical minoxidil, and microneedling. They plan to switch to oral dutasteride and Liposomal Minoxidil Sulfate for better results.

The user shared progress pictures after 2.5 years of using oral minoxidil (5mg daily) and finasteride (1mg daily) for hair loss, noting significant improvements over time. They experienced normal shedding and some beard growth, with no negative side effects reported.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

The user started hair loss treatment at 18 with finasteride and minoxidil, recently switching to dutasteride, and is considering microneedling and a hair transplant. Feedback suggests results are mixed, with some maintaining hair and others suggesting additional treatments like oral minoxidil or microneedling for better absorption.

The user is experiencing a second hair shedding phase after 7 months on finasteride, oral minoxidil, and ketoconazole, and is concerned about the sustainability of the treatment. Others encourage continuing the treatment, explaining that shedding is normal and should stabilize over time.

The user has been using oral finasteride, minoxidil, and biotin for 10 months, noticing some stabilization and thicker baby hairs but not as much progress as expected. They are considering adding topical minoxidil and possibly switching to dutasteride.

User shared 12-month hair loss progress using oral minoxidil, oral dutasteride, and 2% ketoconazole shampoo. They detailed their medication regimen and dosages.

A person transitioning is using 2mg sublingual estradiol and 2.5mg oral minoxidil daily for hair regrowth, noting significant progress in three months. They plan to increase estrogen dosage and consider adding dutasteride, discussing the effects and challenges of transitioning.

A 41-year-old man shared his two-year progress using finasteride for hair regrowth, noting significant improvement but wishing he had started earlier. He plans to add oral minoxidil to his routine despite concerns about potential side effects, emphasizing the importance of starting treatment early to combat hair loss.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The user is considering PRP with exosomes for hair loss after oral minoxidil and dutasteride failed to provide desired results. Despite suggestions for a hair transplant, the user is hesitant due to cost and complexity, and is unsure about other options.